[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2166376T3 - Polielectrolitos de fosfaceno como inmunoadyuvantes. - Google Patents

Polielectrolitos de fosfaceno como inmunoadyuvantes.

Info

Publication number
ES2166376T3
ES2166376T3 ES94923378T ES94923378T ES2166376T3 ES 2166376 T3 ES2166376 T3 ES 2166376T3 ES 94923378 T ES94923378 T ES 94923378T ES 94923378 T ES94923378 T ES 94923378T ES 2166376 T3 ES2166376 T3 ES 2166376T3
Authority
ES
Spain
Prior art keywords
phosphacene
immunoadjuvants
polyelectrolytes
assistant
hydroxylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94923378T
Other languages
English (en)
Inventor
Alexander K Andrianov
Sharon A Jenkins
Lendon G Payne
Bryan E Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Application granted granted Critical
Publication of ES2166376T3 publication Critical patent/ES2166376T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/02—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
    • C08G79/025—Polyphosphazenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

SE DESCRIBE UN POLIELECTROLITO DE POLIFOSFAZENO SOLUBLE INMUNOAYUDANTE. EN UNA REALIZACION, EL AYUDANTE POLIMERICO ES UN POLI(()ORGANOFOSFAZENO()) CON (I) GRUPOS PENDIENTES IONIZADOS O IONIZABLES QUE CONTIENEN, POR EJEMPLO, ACIDO CARBOXILICO, ACIDO SULFONICO, O PARTES DE HIDROXILO, Y (II) GRUPOS PENDIENTES QUE SON SUSCEPTIBLES DE HIDROLISIS BAJO LAS CONDICIONES DE UTILIZACION, PARA DAR BIODEGRADABILIDAD AL POLIMERO.
ES94923378T 1993-07-12 1994-07-08 Polielectrolitos de fosfaceno como inmunoadyuvantes. Expired - Lifetime ES2166376T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/090,841 US5562909A (en) 1993-07-12 1993-07-12 Phosphazene polyelectrolytes as immunoadjuvants

Publications (1)

Publication Number Publication Date
ES2166376T3 true ES2166376T3 (es) 2002-04-16

Family

ID=22224581

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94923378T Expired - Lifetime ES2166376T3 (es) 1993-07-12 1994-07-08 Polielectrolitos de fosfaceno como inmunoadyuvantes.

Country Status (16)

Country Link
US (3) US5562909A (es)
EP (1) EP0710117B1 (es)
JP (1) JPH09500629A (es)
KR (2) KR100352336B1 (es)
CN (1) CN1134265C (es)
AT (1) ATE207505T1 (es)
AU (1) AU691824B2 (es)
BR (1) BR9407051A (es)
CA (1) CA2166208C (es)
DE (1) DE69428795T2 (es)
DK (1) DK0710117T3 (es)
ES (1) ES2166376T3 (es)
NZ (1) NZ269396A (es)
PT (1) PT710117E (es)
SG (1) SG46659A1 (es)
WO (2) WO1995002415A1 (es)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
AU738698B2 (en) * 1994-07-08 2001-09-27 Avant Immunotherapeutics, Inc. Polyphosphazene polyelectrolyte immunoadjuvants
US5855895A (en) * 1995-06-07 1999-01-05 Virus Research Institute Polyphosphazene polyelectrolyte immunoadjuvants
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5891444A (en) * 1995-06-07 1999-04-06 Virus Research Institute, Inc. HIV-1 prophylactic composition and method
US5900238A (en) * 1995-07-27 1999-05-04 Immunex Corporation Vaccine delivery system
WO1997007226A1 (en) * 1995-08-17 1997-02-27 Introgene B.V. Poly(organo)phosphazenes for use in synthetic transfection systems
EP0965336A1 (en) * 1995-11-09 1999-12-22 Microbiological Research Authority Microencapsulated DNA for gene therapy
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
US5898062A (en) * 1996-04-10 1999-04-27 The Penn State Research Foundation Poly (organophosphazene) hydrogels
US5807757A (en) * 1996-07-02 1998-09-15 Virus Research Institute, Inc. Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation
US6303300B1 (en) * 1996-08-16 2001-10-16 Introgen B.V. Poly (organo) phosphazenes for use in synthetic transfection systems
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
US6077662A (en) * 1996-11-27 2000-06-20 Emory University Virus-like particles, methods and immunogenic compositions
WO1998048626A1 (en) * 1997-04-30 1998-11-05 Emory University Methods and compositions for administering dna to mucosal surfaces
US6077916A (en) * 1997-06-04 2000-06-20 The Penn State Research Foundation Biodegradable mixtures of polyphoshazene and other polymers
US5760271A (en) * 1997-08-18 1998-06-02 Virus Research Institute, Inc. Production of polyorganophosphazenes
US6312731B1 (en) * 1997-08-29 2001-11-06 Southern Research Institute Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
US5958414A (en) * 1997-09-03 1999-09-28 Heska Corporation Composition to protect a mammal against Bartonella henselae infection
EP1021168A4 (en) * 1997-10-09 2006-08-30 Univ Vanderbilt MICRO AND NANOAPARTICULAR, POLYMERIC ADMINISTRATION SYSTEM
US6726934B1 (en) 1997-10-09 2004-04-27 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
AU754270B2 (en) 1997-10-20 2002-11-07 Sanofi Pasteur Biologics, Llc Passive immunization against clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6207171B1 (en) * 1998-03-27 2001-03-27 Avant Immunotherapeutics, Inc. Polyphosphazene microspheres
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6506385B1 (en) 1998-04-17 2003-01-14 Embrex, Inc. Live vaccines and methods of treatment therewith
WO1999058134A1 (en) * 1998-05-11 1999-11-18 Purdue Research Foundation Methods and compositions for nucleic acid delivery
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US6696089B2 (en) 1998-09-03 2004-02-24 Board Of Regents Of The University Of Nebraska Nanogel networks including polyion polymer fragments and biological agent compositions thereof
US5952232A (en) * 1998-09-17 1999-09-14 Rothman; James Edward Expandible microparticle intracellular delivery system
US6261573B1 (en) * 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
WO2000035481A2 (en) 1998-12-17 2000-06-22 Connaught Laboratories Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
WO2000041732A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6586501B1 (en) 1999-01-20 2003-07-01 Cabot Corporation Aggregates having attached polymer groups and polymer foams
US6258864B1 (en) 1999-01-20 2001-07-10 Cabot Corporation Polymer foam containing chemically modified carbonaceous filler
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
AU1186401A (en) 1999-06-23 2001-01-22 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
EP1196430B1 (en) * 1999-06-29 2012-02-15 MannKind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
WO2001015727A2 (en) * 1999-09-02 2001-03-08 Antigenics Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
EP1228095B1 (en) 1999-10-22 2008-04-09 Sanofi Pasteur Limited Modified gp100 and uses thereof
GB0000001D0 (en) * 2000-01-05 2000-02-23 Du Pont Uk Pharmaceutical compositions and their preparation
JP2004500918A (ja) 2000-04-11 2004-01-15 ポリゼニックス　ゲーエムベーハー ポリ−トリ−フルオロ−エトキシポリホスファゼンカバーリングおよびフィルム
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
ES2276788T3 (es) 2000-05-10 2007-07-01 Sanofi Pasteur Limited Polipeptidos inmunogenos codificados por minigenes mage y sus utilizaciones.
AU2001282854A1 (en) * 2000-06-29 2002-01-14 The Penn State Research Foundation Linear polyphosphazenes and gel polymer electrolytes containing same
US6740409B1 (en) * 2000-11-15 2004-05-25 Board Of Trustees Of University Of Illinois Polymer films
DE10100961B4 (de) 2001-01-11 2005-08-04 Polyzenix Gmbh Körperverträglicher Werkstoff und mit diesem Werkstoff beschichtetes Substrat für die Züchtung von Zellen und künstlichen aus Zellen aufgebauten oder gewachsenen organischen Implantaten
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
ES2178961B1 (es) * 2001-03-06 2004-07-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
JP2005514326A (ja) * 2001-07-10 2005-05-19 コリクサ コーポレイション ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
CA2457018C (en) 2001-08-17 2010-12-14 Polyzenix Gmbh Device based on nitinol, a process for its production and its use
AU2002365414A1 (en) * 2001-11-29 2003-06-10 Parallel Solutions, Inc. Copolymer libraries and production and use thereof
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
WO2003082316A1 (en) * 2002-03-29 2003-10-09 The Regents Of The University Of California Microgel particles for the delivery of bioactive materials
DE10224352A1 (de) * 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
US20080226723A1 (en) * 2002-07-05 2008-09-18 Celonova Biosciences, Inc. Loadable Polymeric Particles for Therapeutic Use in Erectile Dysfunction and Methods of Preparing and Using the Same
AU2003269904A1 (en) * 2002-07-10 2004-01-23 The Ohio State University Research Foundation Antigen-polymer compositions
US20040161470A1 (en) * 2002-11-22 2004-08-19 Alexander Andrianov Preparation of polyphosphazene microspheres
US20040131631A1 (en) * 2002-11-22 2004-07-08 Alexander Andrianov Polyphosphazene immunostimulants
ITMI20031617A1 (it) * 2003-08-06 2005-02-07 Fond Carlo E Dirce Callerio Onlus Microcapsule a doppio strato di polisaccaridi utilizzabili
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
CN101027082A (zh) * 2004-01-12 2007-08-29 曼恩坎德公司 降低2型糖尿病患者血清胰岛素原水平的方法
DE502004010393D1 (de) * 2004-03-04 2009-12-31 Leukocare Gmbh Leukozytenstimulations-Matrix
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US7074256B2 (en) * 2004-05-13 2006-07-11 Battelle Energy Alliance, Llc Phosphazene membranes for gas separations
EP1786784B1 (en) 2004-08-20 2010-10-27 MannKind Corporation Catalysis of diketopiperazine synthesis
KR20150039211A (ko) 2004-08-23 2015-04-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
WO2006035418A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US20210299056A9 (en) 2004-10-25 2021-09-30 Varian Medical Systems, Inc. Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
JP4885866B2 (ja) 2004-10-25 2012-02-29 セロノヴァ バイオサイエンスィズ ジャーマニー ゲーエムベーハー 治療適用および／または診断適用のための充填可能なポリホスファゼン含有粒子、ならびにその調製方法および使用方法
US20060193820A1 (en) * 2005-02-18 2006-08-31 Andrianov Alexander K Immunostimulating polyphosphazene compounds
US8741454B2 (en) * 2005-03-29 2014-06-03 Toyota Motor Engineering & Manufacturing North America, Inc. Proton exchange membrane for fuel cell
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
KR100784485B1 (ko) * 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
MX360812B (es) 2006-02-22 2018-11-16 Mannkind Corp Un método para mejorar las propiedades farmacéuticas de micropartículas que contienen dicetopiperazina y un agente activo.
AU2007238114B2 (en) 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2008045949A2 (en) 2006-10-10 2008-04-17 Celonova Biosciences, Inc. Bioprosthetic heart valve with polyphosphazene
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US20080282455A1 (en) * 2007-05-18 2008-11-20 Higher Dimension Materials, Inc. Flame resistant and heat protective flexible material with intumescing guard plates and method of making the same
CA2692740A1 (en) * 2007-07-09 2009-01-15 Apogee Technology, Inc. Immunostimulating polyphosphazene compounds for intradermal immunization
US20090016935A1 (en) * 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
EP2674169B1 (en) 2007-09-11 2015-01-28 University Of Guelph Polysaccharide immunogens from Clostridium difficile
KR101679812B1 (ko) 2007-09-14 2016-11-28 사노피 파스테르 바이오로직스, 엘엘씨 클로스트리듐 디피실리 톡소이드 ａ 및 ｂ를 포함하는 약학적 조성물
US20090111763A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable polymeric particles for bone augmentation and methods of preparing and using the same
US20090110738A1 (en) * 2007-10-26 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Particles for Cosmetic and Reconstructive Tissue Augmentation Applications and Methods of Preparing and Using the Same
EP2212350B1 (en) 2007-10-26 2013-08-28 Governing Council of the University of Toronto Treating chronic viral infection by targetting TIM-3
US20090110731A1 (en) * 2007-10-30 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Microparticles for Therapeutic Use in Alopecia and Methods of Preparing and Using the Same
US20090110730A1 (en) * 2007-10-30 2009-04-30 Celonova Biosciences, Inc. Loadable Polymeric Particles for Marking or Masking Individuals and Methods of Preparing and Using the Same
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
TWI677355B (zh) 2008-06-13 2019-11-21 美商曼凱公司 用於藥物傳輸之乾粉吸入器及系統
EP2300083B1 (en) 2008-06-20 2013-05-22 MannKind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US9061001B2 (en) * 2008-10-16 2015-06-23 University Of Saskatchewan Combination adjuvant formulation
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
CA2759727A1 (en) * 2009-04-22 2010-10-28 Board Of Regents, The University Of Texas System Hydrogels for combinatorial delivery of immune-modulating biomolecules
BRPI1012196B1 (pt) 2009-05-18 2021-11-30 Sublimity Therapeutics Limited Composição compreendendo gotas de óleo
SG176738A1 (en) 2009-06-12 2012-01-30 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
CN102695500A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 多糖基水凝胶
CN107033368A (zh) 2009-11-09 2017-08-11 聚光灯技术合伙有限责任公司 碎裂水凝胶
US9252455B1 (en) * 2010-04-14 2016-02-02 Hrl Laboratories, Llc Lithium battery structures employing composite layers, and fabrication methods to produce composite layers
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
CN103826988B (zh) 2011-04-01 2016-03-09 曼金德公司 用于药物药盒的泡罩包装
CN102219911B (zh) * 2011-04-28 2012-10-17 北京化工大学 一种可注射聚膦腈/明胶复合水凝胶及其制备方法
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
US9320785B2 (en) * 2012-01-20 2016-04-26 Fernando Thome Kreutz Autologous cancer cell vaccine
WO2013116639A1 (en) 2012-02-01 2013-08-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter immunogenic compositions and uses thereof
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
CN103110941B (zh) * 2012-10-09 2014-09-03 江苏康为世纪生物科技有限公司 一种新型免疫佐剂及快速免疫方案
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10098940B2 (en) 2014-06-20 2018-10-16 University Of Saskatchewan Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
KR20170102223A (ko) 2014-11-07 2017-09-08 시그모이드 파마 리미티드 사이클로스포린을 포함하는 조성물
KR101762003B1 (ko) 2015-07-16 2017-07-26 연세대학교 산학협력단 경구용 바이러스 백신 전달체
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
KR20180085736A (ko) 2015-11-09 2018-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체
EP3377560A4 (en) * 2015-11-18 2019-07-17 University of Maryland, College Park POLYPHOSPHAZENE, PROCESS FOR THE PREPARATION AND USE THEREOF
US10858483B2 (en) * 2016-07-06 2020-12-08 University Of Maryland, College Park Polyphosphazene polyelectrolytes and uses thereof
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) * 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2019173871A1 (en) * 2018-03-13 2019-09-19 Capsular Technologies Pty Ltd Vaccine composition
US11397282B1 (en) 2018-06-29 2022-07-26 Hrl Laboratories, Llc Infrared-transparent polymer optics and methods of making and using the same
KR102115708B1 (ko) * 2019-01-10 2020-05-27 서울대학교산학협력단 하이드로겔에 의해 캡슐화된 불활성화 균체를 포함하는 경구 투여용 백신 조성물
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
US20200383932A1 (en) 2019-06-05 2020-12-10 The Florida International University Board Of Trustees Biotherapy for viral infections using biopolymer based micro/nanogels
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3893980A (en) * 1974-03-29 1975-07-08 Pennsylvania Res Corp Poly(amino acid alkyl ester phosphazenes)
FR2321896A1 (fr) * 1975-08-29 1977-03-25 Anvar Agents adjuvants immunologiques actifs en solution aqueuse
US4055520A (en) * 1976-07-14 1977-10-25 Armstrong Cork Company Polyphosphazene blends
US4026839A (en) * 1976-08-30 1977-05-31 Armstrong Cork Company Polyphosphazene polymer/silicone rubber blends and foams therefrom
US4209014A (en) * 1977-12-12 1980-06-24 Canadian Patents And Development Limited Dispensing device for medicaments
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4636387A (en) * 1982-06-21 1987-01-13 Research Corporation Anesthetic polyorganophosphazenes
US4495174A (en) * 1982-06-21 1985-01-22 Research Corporation Anesthetic polyorganophosphazenes
US4451647A (en) * 1982-06-21 1984-05-29 Research Corporation Heparinized polyorganophosphazenes
US4440921A (en) * 1982-06-21 1984-04-03 Research Corporation Coupling of polyorganophosphazenes to carboxylic acid
US4639366A (en) * 1984-06-06 1987-01-27 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4880622A (en) * 1986-05-20 1989-11-14 Research Corporation Technologies, Inc. Water-soluble phosphazene polymers having pharmacological applications
NZ221306A (en) * 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
US4975280A (en) * 1989-01-23 1990-12-04 Ethyl Corporation Bioerodable sustained release implants
US4946938A (en) * 1989-08-01 1990-08-07 The University Of Pittsburgh A process for the catalytic synthesis of polyphosphazenes
US5104947A (en) * 1989-08-07 1992-04-14 Ethyl Corporation Polyphosphazenes and their synthesis
US5053451A (en) * 1990-01-19 1991-10-01 The Pennsylvania Research Corporation Ionically cross-linkable polyphosphazene: poly(bis(carboxylatophenoxy) phosphazene) and its hydrogels and membranes
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
JPH06500405A (ja) * 1991-05-14 1994-01-13 ブルースカイ　リサーチ　インコーポレイテッド 動的シアリング干渉計

Also Published As

Publication number Publication date
KR100353496B1 (ko) 2003-03-03
DE69428795T2 (de) 2002-06-13
CA2166208C (en) 2010-04-20
US5494673A (en) 1996-02-27
DE69428795D1 (de) 2001-11-29
US5529777A (en) 1996-06-25
CN1128954A (zh) 1996-08-14
AU7326194A (en) 1995-02-13
PT710117E (pt) 2002-04-29
WO1995002628A1 (en) 1995-01-26
US5562909A (en) 1996-10-08
DK0710117T3 (da) 2002-02-18
EP0710117A4 (en) 1996-08-07
EP0710117B1 (en) 2001-10-24
KR100352336B1 (ko) 2003-04-16
WO1995002415A1 (en) 1995-01-26
EP0710117A1 (en) 1996-05-08
AU691824B2 (en) 1998-05-28
NZ269396A (en) 1999-09-29
BR9407051A (pt) 1996-08-13
CN1134265C (zh) 2004-01-14
KR960703620A (ko) 1996-08-31
JPH09500629A (ja) 1997-01-21
KR960703617A (ko) 1996-08-31
SG46659A1 (en) 1998-02-20
ATE207505T1 (de) 2001-11-15
CA2166208A1 (en) 1995-01-26

Similar Documents

Publication Publication Date Title
ES2166376T3 (es) Polielectrolitos de fosfaceno como inmunoadyuvantes.
ES2084688T3 (es) Conjugados de polipeptido-polimero para el tratamiento de heridas.
BR9802609A (pt) Composição, e, processo para preparar um polìmero hase neutralizado.
MX9602545A (es) Esterilizacion con acido peracetico.
ATE287705T1 (de) Wärmegellierende bioabbaubare wässrige polymerlösung
ES2090065T3 (es) Esteres de acido fosforico, procedimiento para su fabricacion y su utilizacion como agente dispersante.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
ES2087894T3 (es) Compuesto de lavado suavizante para tejidos en detergente liquido.
BR9814217A (pt) Géis super-absorventes baseados na poli (vinilguanidina)
ES2098323T3 (es) Sistema doble redox para la desinfeccion de lentes de contacto.
ES2099464T3 (es) Procedimiento para la produccion de acido (poli)lactico.
ES2137216T3 (es) Agentes de revestimiento acuosos y su uso para la produccion de revestimientos permeables al vapor de agua.
ES2065521T3 (es) Mejoras en los sistemas de datos de radio.
ES2052620T3 (es) Barras de gel basado en jabon.
ES2188923T3 (es) Procedimiento de preparacion de resinas de polieterester a partir de diesteres diolicos.
ES2067566T3 (es) Poli (naftalato de etileno) modificado.
AR016925A1 (es) Tratamiento de tres plantulas para fomentar el indice de supervivencia
MX9307007A (es) Vectores de expresion para tripsina y tripsinogeno de bovino y celulashuesped transformadoras con los mismos.
ES2085856T3 (es) Ester derivado de un siloxano con grupos alcoholes; composiciones cosmeticas que contienen estos derivados.
ATE180676T1 (de) Adjuvans für impstoffe
AR017470A1 (es) Polimeros de poliestercarbonatos y metodo para su preparacion
ES2093483T3 (es) Electrolito polimerico a base de polieter solido.
AR015370A1 (es) Un procedimiento para la produccion de copoliesteres claros de acido tereftalico, acido naftalendicarboxilico y etilen glicol.
ES2093020T3 (es) Polimeros y composiciones detergentes que los contienen.
ES2132636T3 (es) Polieter-glicoles y -alcoholes obtenidos a partir de 3,4-epoxi-1-buteno.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710117

Country of ref document: ES